Inosine

Generic Name
Inosine
Brand Names
Rejuvesol
Drug Type
Small Molecule
Chemical Formula
C10H12N4O5
CAS Number
58-63-9
Unique Ingredient Identifier
5A614L51CT
Background

A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)

Indication

The primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects.

Associated Conditions
-
Associated Therapies
Rejuvenation of a unit of RBC
Clinical Trials
Related News

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

First Posted Date
2024-04-09
Last Posted Date
2024-04-09
Lead Sponsor
Fudan University
Target Recruit Count
10
Registration Number
NCT06355024

Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy

Phase 1
Not yet recruiting
Conditions
Cerebrovascular Disorders
Acute Cerebrovascular Disease
Interventions
Drug: iNO
First Posted Date
2023-05-23
Last Posted Date
2024-11-27
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
27
Registration Number
NCT05871606
Locations
🇺🇸

Carolinas Medical Center, Charlotte, North Carolina, United States

🇺🇸

Atrium Health, Charlotte, North Carolina, United States

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

Phase 3
Withdrawn
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Placebo
Drug: iNO
First Posted Date
2018-07-27
Last Posted Date
2023-02-21
Lead Sponsor
Bellerophon Pulse Technologies
Registration Number
NCT03602781
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇨🇦

Peter Lougheed Centre, Calgary, Alberta, Canada

🇨🇦

Toronto General Hospital, University Health Network, Toronto, Ontario, Canada

and more 1 locations

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo
Drug: Inosine
First Posted Date
2017-05-30
Last Posted Date
2021-02-18
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
48
Registration Number
NCT03168711
Locations
🇺🇸

Holy Cross Hospital, Fort Lauderdale, Florida, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

First Posted Date
2017-03-15
Last Posted Date
2023-02-16
Lead Sponsor
Duke University
Target Recruit Count
519
Registration Number
NCT03081052
Locations
🇺🇸

Duke Health, Durham, North Carolina, United States

Study of Urate Elevation in Parkinson's Disease, Phase 3

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
Drug: Inosine
First Posted Date
2015-12-30
Last Posted Date
2020-07-28
Lead Sponsor
Michael Alan Schwarzschild
Target Recruit Count
298
Registration Number
NCT02642393
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

SUNY Upstate Medical University, Syracuse, New York, United States

and more 59 locations

A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Inosine
First Posted Date
2015-11-25
Last Posted Date
2017-03-29
Lead Sponsor
Michael Alan Schwarzschild
Target Recruit Count
18
Registration Number
NCT02614469
Locations
🇺🇸

Covance Clinical Research Unit Inc., Evansville, Indiana, United States

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

Phase 1
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Inosine
First Posted Date
2014-11-11
Last Posted Date
2017-11-06
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
32
Registration Number
NCT02288091
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

First Posted Date
2010-10-14
Last Posted Date
2020-08-19
Lead Sponsor
University of Oklahoma
Target Recruit Count
33
Registration Number
NCT01220687
Locations
🇺🇸

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

🇺🇸

University of Oklahoma, Childrens Hospital, Oklahoma City, Oklahoma, United States

Safety of Urate Elevation in Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson Disease
Interventions
Drug: Placebo
Drug: inosine
First Posted Date
2009-02-02
Last Posted Date
2014-06-05
Lead Sponsor
The Parkinson Study Group
Target Recruit Count
75
Registration Number
NCT00833690
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 13 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy